Adage Capital Partners
TVTX icon

Adage Capital Partners’s Travere Therapeutics TVTX Stock Holding History

Adage Capital Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29M Sell
977,000
-1,950,000
-67% -$58.3M 0.04% 377
2025
Q4 		$112M Sell
2,927,000
-625,000
-18% -$20.3M 0.17% 115
2025
Q3 		$84.9M Buy
3,552,000
+768,000
+28% +$14.4M 0.13% 154
2025
Q2 		$41.2M Buy
2,784,000
+599,102
+27% +$9.93M 0.07% 279
2025
Q1 		$39.2M Buy
2,184,898
+1,808,098
+480% +$36.7M 0.07% 281
2024
Q4 		$6.56M Sell
376,800
-23,200
-6% -$410K 0.01% 681
2024
Q3 		$5.6M Hold
400,000
– – 0.01% 704
2024
Q2 		$3.29M Sell
400,000
-100,000
-20% -$673K 0.01% 749
2024
Q1 		$3.85M Hold
500,000
– – 0.01% 723
2023
Q4 		$4.5M Buy
+500,000
New +$3.64M 0.01% 690
2023
Q2 		– Sell
-4,113,962
Closed -$92.5M – 931
2023
Q1 		$92.5M Buy
4,113,962
+1,513,962
+58% +$32.2M 0.21% 116
2022
Q4 		$54.7M Buy
2,600,000
+250,000
+11% +$5.3M 0.13% 190
2022
Q3 		$57.9M Buy
2,350,000
+400,000
+21% +$10.3M 0.14% 162
2022
Q2 		$47.2M Buy
1,950,000
+447,508
+30% +$11.3M 0.11% 200
2022
Q1 		$38.7M Buy
1,502,492
+200,000
+15% +$5.31M 0.07% 285
2021
Q4 		$40.4M Sell
1,302,492
-397,508
-23% -$11.2M 0.07% 279
2021
Q3 		$41.2M Sell
1,700,000
-1,893,763
-53% -$34.8M 0.08% 250
2021
Q2 		$52.4M Sell
3,593,763
-956,237
-21% -$18.9M 0.1% 205
2021
Q1 		$114M Buy
4,550,000
+1,700,000
+60% +$47M 0.23% 91
2020
Q4 		$77.7M Buy
2,850,000
+1,315,500
+86% +$30.7M 0.17% 131
2020
Q3 		$28.3M Sell
1,534,500
-100,000
-6% -$1.94M 0.07% 293
2020
Q2 		$33.4M Buy
1,634,500
+592,702
+57% +$9.44M 0.09% 266
2020
Q1 		$15.2M Buy
1,041,798
+966,798
+1,289% +$14.5M 0.05% 384
2019
Q4 		$1.06M Sell
75,000
-25,000
-25% -$319K ﹤0.01% 679
2019
Q3 		$1.16M Buy
+100,000
New +$1.65M ﹤0.01% 678

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners's TVTX Position: Q1 2026 in Review

Adage Capital Partners reduced its Travere Therapeutics (TVTX) stake by 67% in Q1 2026, selling an estimated $58.3M and leaving 977,000 shares worth $29M. The position accounts for 0.04% of the portfolio, ranked #377.

Adage Capital Partners first reported a position in TVTX in Q3 2019 and has held it in 25 quarters since. The position peaked at $114M in Q1 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Adage Capital Partners held 977,000 shares of Travere Therapeutics worth $29M as of Q1 2026.
  • Adage Capital Partners sold 1,950,000 Travere Therapeutics shares in Q1 2026, an estimated $58.3M.
  • Travere Therapeutics made up 0.04% of Adage Capital Partners's portfolio in Q1 2026, its #377 holding.
  • Adage Capital Partners first reported a position in Travere Therapeutics in Q3 2019 and has held it in 25 quarters since.
  • Adage Capital Partners's Travere Therapeutics position peaked at $114M in Q1 2021.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.